283 related articles for article (PubMed ID: 15861931)
1. Pharmacogenetics as a tool in the therapy of schizophrenia.
Wilffert B; Zaal R; Brouwers JR
Pharm World Sci; 2005 Feb; 27(1):20-30. PubMed ID: 15861931
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research.
Arranz MJ; de Leon J
Mol Psychiatry; 2007 Aug; 12(8):707-47. PubMed ID: 17549063
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia--an update.
Scharfetter J
Pharmacogenomics; 2004 Sep; 5(6):691-8. PubMed ID: 15335289
[TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of response to antipsychotics in patients with schizophrenia.
Arranz MJ; Rivera M; Munro JC
CNS Drugs; 2011 Nov; 25(11):933-69. PubMed ID: 22054119
[TBL] [Abstract][Full Text] [Related]
5. [Clinical pharmacogenetics in the treatment of schizophrenia].
Saito M; Yasui-Furukori N; Kaneko S
Nihon Shinkei Seishin Yakurigaku Zasshi; 2005 Jun; 25(3):129-35. PubMed ID: 16045195
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of treatment in first-episode schizophrenia: D3 and 5-HT2C receptor polymorphisms separately associate with positive and negative symptom response.
Reynolds GP; Yao Z; Zhang X; Sun J; Zhang Z
Eur Neuropsychopharmacol; 2005 Mar; 15(2):143-51. PubMed ID: 15695058
[TBL] [Abstract][Full Text] [Related]
7. Interactive effect of cytochrome P450 17alpha-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia.
Segman RH; Heresco-Levy U; Yakir A; Goltser T; Strous R; Greenberg DA; Lerer B
Biol Psychiatry; 2002 Feb; 51(3):261-3. PubMed ID: 11839369
[TBL] [Abstract][Full Text] [Related]
8. [Clinical pharmacogenetics in the treatment of schizophrenia].
Furukori N
Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Apr; 30(2):65-9. PubMed ID: 20491279
[TBL] [Abstract][Full Text] [Related]
9. Dopamine D3 receptor variant and tardive dyskinesia.
Rietschel M; Krauss H; Müller DJ; Schulze TG; Knapp M; Marwinski K; Maroldt AO; Paus S; Grünhage F; Propping P; Maier W; Held T; Nöthen MM
Eur Arch Psychiatry Clin Neurosci; 2000; 250(1):31-5. PubMed ID: 10738862
[TBL] [Abstract][Full Text] [Related]
10. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Zhang Z; Hou G; Zhang X; Yao H; Sha W; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2003 Apr; 20(2):98-102. PubMed ID: 12673575
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenetics in psychosis.
Collier DA
Drug News Perspect; 2003 Apr; 16(3):159-65. PubMed ID: 12819814
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and antipsychotics in the light of personalized pharmacotherapy.
Mihaljević-Peles A; Sagud M; Bozina N; Zivković M; Jovanović N
Psychiatr Danub; 2010 Jun; 22(2):335-7. PubMed ID: 20562776
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomics in schizophrenia: the quest for individualized therapy.
Basile VS; Masellis M; Potkin SG; Kennedy JL
Hum Mol Genet; 2002 Oct; 11(20):2517-30. PubMed ID: 12351588
[TBL] [Abstract][Full Text] [Related]
15. Serotonin and dopamine receptor gene polymorphisms and the risk of extrapyramidal side effects in perphenazine-treated schizophrenic patients.
Gunes A; Scordo MG; Jaanson P; Dahl ML
Psychopharmacology (Berl); 2007 Mar; 190(4):479-84. PubMed ID: 17102980
[TBL] [Abstract][Full Text] [Related]
16. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
17. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment.
Reynolds GP; Templeman LA; Zhang ZJ
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):1021-8. PubMed ID: 15953671
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics and antipsychotic treatment response.
Naumovska Z; Nestorovska AK; Filipce A; Sterjev Z; Brezovska K; Dimovski A; Suturkova LJ
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(1):53-67. PubMed ID: 26076775
[TBL] [Abstract][Full Text] [Related]
19. Risperidone-related weight gain: genetic and nongenetic predictors.
Lane HY; Liu YC; Huang CL; Chang YC; Wu PL; Lu CT; Chang WH
J Clin Psychopharmacol; 2006 Apr; 26(2):128-34. PubMed ID: 16633140
[TBL] [Abstract][Full Text] [Related]
20. The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.
Fleeman N; McLeod C; Bagust A; Beale S; Boland A; Dundar Y; Jorgensen A; Payne K; Pirmohamed M; Pushpakom S; Walley T; de Warren-Penny P; Dickson R
Health Technol Assess; 2010 Jan; 14(3):1-157, iii. PubMed ID: 20031087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
